Healthcare bearish stocks: Intrexon Corp (NYSE:XON), Cynosure (NASDAQ:CYNO), Capital Senior Living Corporation (NYSE:CSU), Avanir Pharmaceuticals (NASDAQ:AVNR)



Intrexon Corp (NYSE:XON) recently appointed James S. Turley. Mr. Turley’s effective direction of a global organization during some challenging economic times instilled the trust and confidence of key stakeholders, and Intrexon believes that his appointment to the Board as an independent director is in keeping with the best practices of corporate governance and providing guidance to the Company’s team. Intrexon Corp (NYSE:XON) stock performance was -11.14% in last session and finished the day at $ 15.39. Traded volume was 1,403,677 shares in the last session and the average volume of the stock remained 809,205 shares. The beta of the stock remained -13.182. Intrexon Corp (NYSE:XON) insider ownership is 0.30%.

Cynosure (NASDAQ:CYNO) announced its earnings results on Tuesday. The company reported $0.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by $0.04, AnalystRatings.Net reports. Cynosure, Inc. (NASDAQ:CYNO)dropped -6.63% to $ 21.11 yesterday on volume of 631,757 shares. The intra-day range of the stock was $ 19.14 – 22.97. Cynosure, Inc. (NASDAQ:CYNO) has a market capitalization of $ 469.97 million.

Capital Senior Living (NYSE:CSU) announced its earnings results on Tuesday. The company reported $0.01 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.04 by $0.03, Stock Ratings Network reports. Capital Senior Living Corporation (NYSE:CSU)’s stock on May 7, 2014 reported a decrease of -6.01% to the closing price of $ 22.99. Its fifty two weeks range is $ 19.87 – 27.10. The total market capitalization recorded $ 643.12 million. The overall volume in the last trading session was 539,766 shares. In its share capital, Capital Senior Living Corporation(NYSE:CSU) has 29.01 million outstanding shares.

Avanir Pharmaceuticals (NASDAQ:AVNR) posted its quarterly earnings results on Tuesday. The company reported ($0.08) earnings per share for the quarter, meeting the analysts’ consensus estimate of ($0.08), AR Network reports. On Friday, shares of Avanir Pharmaceuticals Inc (NASDAQ:AVNR)dropped -6.72% to close the day at $ 4.44. Company return on investment (ROI) is -149.40% and its monthly performance is recorded as 28.32%. Avanir Pharmaceuticals Inc (NASDAQ:AVNR) quarterly revenue growth is 24.72%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone